Mumbai, Aug. 8 -- Profit before tax (PBT) dropped 91.5% to Rs 96.90 crore in Q1 FY26 compared with Rs 1145.50 crore in Q1 FY25.

The company reported a one-time gain of Rs 1,075 crore in Q1 FY25 from divestment of its branded formulations India (BFI) business.

Core EBITDA stood at Rs 1,003 crore in Q1 June 2025, registering the growth of 11% compared with Rs 903 crore in Q1 FY25. Core EBITDA excludes impact of forex, R&D expense, licensing income, BFI divestment gain, and mark-to-market movement on investments.

Core EBITDA margin fell to 25% in Q1 FY26 compared with Rs 26% in Q1 FY25.

Revenue from generics business increased 6% YoY to Rs 697 crore during the quarter. Revenue from biosimilars business stood at Rs 2,458 crore, registerin...